Citizen in a RepublicNH Bill Briefing
← All bills

SB 455 · 2026 · Senate · Health and Human Services Committee

Medicaid coverage for GLP-1 medications

AI-generated

(New Title) relative to coverage for GLP-1 medication under the state Medicaid plan.

Directs the department of health and human services to cover GLP-1 medication under the state Medicaid plan when medically necessary for certain health conditions.AI-generated

Status

Killed in the House — Inexpedient to Legislate · May 14, 2026
  1. ✓Introduced
  2. ✓Senate
  3. ✕House
  4. Governor
  5. Law

Analysis

This bill requires health plans to cover GLP-1 medications under certain circumstances.

From the bill's official ANALYSIS section.

Official record

Bill page — docket & status

gc.nh.gov · the authoritative source

Sponsors

Sen. Suzanne PrentissDPrimeAssistant Democratic Leader

Public testimony

20 signed in online · 5 wrote testimony

95% support0% oppose5% neutral

In their wordsVerbatim, exactly as submitted

“Type II diabetes is more prevalent in low income groups. Untreated diabetes resulting in serious complications including vascular diseases, kidney failure, loss of eyesight, and comorbidities including obesity, heart disease and hypertension cost so much more than the GLP-1 medications that mitigate and prevent them.…”
— Janet Lucas, Camptonsupports
“My name is Joseph Zucchi, PA-C, and I am a Physician Associate and Clinical Supervisor at Transition Medical Weight Loss in Salem, New Hampshire.…”
— Joseph Zucchi, Salemsupports
“I support SB 455 because it establishes clear, medically grounded criteria for GLP-1 coverage and prevents insurers from using opaque or inconsistent rules to deny evidence-based treatment.…”
— Hannah Meiselman, Manchestersupports
“Dear House Commerce and Consumer Affairs Committee, I am pleased to share a Policy Research Shop brief that my students researched and wrote over the winter term at Dartmouth College providing a cost-benefit analysis of GLP-1 coverage for obesity in New Hampshire.…”
— Kristin Smith, Hanoverneutral

Verbatim excerpts of submitted testimony, quoted from the testimony tool.

Read the testimony · as of Aug 12, 2026

Hearings

  • 2026-02-119:00 amSenate Health and Human ServicesSH 100Public hearing
  • 2026-04-1510:30 amHouse Commerce and Consumer AffairsGP 229Public hearing
  • 2026-04-2210:00 amHouse Commerce and Consumer AffairsGP 229Public hearing
  • 2026-04-2910:00 amHouse Commerce and Consumer AffairsGP 229Public hearing

Legislative history

  1. Jan 7, 2026SenIntroduced 01/07/2026 and Referred to Health and Human Services; SJ 1
  2. Feb 11, 2026SenHearing: 02/11/2026, Room 100, SH, 01:00 pm; SC 5
  3. Mar 5, 2026Sen: Ought to Pass with Amendment # 2026-0836s, 03/05/2026; Vote 5-0; CC; SC 8
  4. Mar 5, 2026SenCommittee Amendment # 2026-0836s, AA, VV; 03/05/2026; SJ 5
  5. Mar 5, 2026SenOught to Pass with Amendment #2026-0836s, MA, VV; OT3rdg; 03/05/2026; SJ 5
  6. Mar 12, 2026HouseIntroduced (in recess of) 03/12/2026 and referred to Commerce and Consumer Affairs HJ 8 P. 114
  7. Apr 15, 2026HousePublic Hearing: 04/15/2026 10:30 am GP 229
  8. Apr 22, 2026HouseSubcommittee Work Session: 04/22/2026 10:00 am GP 229
  9. Apr 29, 2026HouseExecutive Session: 04/29/2026 10:00 am GP 229
  10. Apr 29, 2026House: Inexpedient to Legislate 04/29/2026 (Vote 13-2; RC) HC 19 P. 17
  11. May 14, 2026HouseInexpedient to Legislate: MA VV 05/14/2026 HJ 13 P. 26

Coverage

No reporting linked yet.

Documents (PDF)

Bill text & amendments link direct to gc.nh.gov; committee reports stream from the state record.